Maxilin (Clarithromycin)

Clarithromycin is a macrolide antibiotic that targets bacterial infections of the respiratory and skin pathways, offering a broad spectrum of activity against susceptible organisms.

• Community‑acquired pneumonia: achieves bacterial eradication in the lungs, improving symptoms and reducing mortality in adult patients.
• Skin and soft tissue infections: reduces bacterial load in cellulitis, abscesses and wound infections, facilitating faster healing.
• Upper respiratory tract infections: eliminates common respiratory pathogens, alleviating cough, sore throat and sinus involvement.
• Bronchitis: controls bacterial exacerbations, shortening disease duration and preventing complications.

• Clarithromycin binds to the 50S subunit of bacterial ribosomes, blocking the translocation step of protein synthesis. This inhibition prevents elongation of the peptide chain, halting bacterial growth. The drug exhibits a bacteriostatic effect against susceptible Gram‑positive and some Gram‑negative organisms, and at higher concentrations may become bactericidal, also interfering with bacterial toxin production.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Taste disturbance: altered or metallic taste.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or jaundice.
• QT prolongation: cardiac rhythm disturbance.
• Severe allergic reaction: anaphylaxis or angioedema.
• Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth.

Clarithromycin requires careful monitoring in several clinical situations.

• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Hepatic dysfunction: monitor liver enzymes during therapy.
• Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances.
• Drug interactions: review concomitant medications for potential CYP3A4 interactions.
• Pregnancy: category B, use only if benefit outweighs risk.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Clarithromycin can interact with several medicines; clinicians should assess risk before co‑administration.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (rifampin, carbamazepine): may markedly lower clarithromycin exposure.
• Anticoagulants (warfarin): increased anticoagulant effect, monitor INR closely.
• QT‑prolonging agents (amiodarone, quinidine): risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Statins (simvastatin, lovastatin): elevated risk of myopathy, consider dose adjustment.
• Theophylline: increased serum concentrations, monitor for toxicity.
• Oral contraceptives: possible reduced effectiveness, advise additional contraception.